Administration, Metronomic
"Administration, Metronomic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Administration of low doses of a drug or a drug combination over prolonged periods of time usually at a regular interval.
| Descriptor ID |
D059250
|
| MeSH Number(s) |
E02.319.283.199
|
| Concept/Terms |
Administration, Metronomic- Administration, Metronomic
- Administrations, Metronomic
- Metronomic Administration
- Metronomic Administrations
- Metronomic Drug Therapy
- Drug Therapies, Metronomic
- Drug Therapy, Metronomic
- Metronomic Drug Therapies
- Metronomic Drug Administration
- Drug Administration, Metronomic
- Drug Administrations, Metronomic
- Metronomic Drug Administrations
|
Below are MeSH descriptors whose meaning is more general than "Administration, Metronomic".
Below are MeSH descriptors whose meaning is more specific than "Administration, Metronomic".
This graph shows the total number of publications written about "Administration, Metronomic" by people in this website by year, and whether "Administration, Metronomic" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 3 | 3 |
| 2018 | 0 | 3 | 3 |
| 2019 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Administration, Metronomic" by people in Profiles.
-
De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option? Crit Rev Oncol Hematol. 2021 Jan; 157:103148.
-
Metronomic chemotherapy for scheduling oral cancer surgery during the COVID-19 pandemic. Indian J Cancer. 2020 Oct-Dec; 57(4):481-484.
-
Metronomic chemotherapy for patients with metastatic breast cancer: Review of effectiveness and potential use during pandemics. Cancer Treat Rev. 2020 Sep; 89:102066.
-
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. Eur J Cancer. 2019 09; 119:151-157.
-
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer. 2019 06; 132:17-23.
-
Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer. Biomed Res Int. 2018; 2018:6278403.
-
Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol. 2018 03; 19(3):323-336.
-
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jan 01; 4(1):93-97.
-
Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients. Oncotarget. 2017 Jul 18; 8(29):47161-47166.
-
Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep. 2017 02 13; 7:42499.